Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 81 clinical trials
Featured trial
Avelumab in UroThelIal CarcInoma-PATRIOIT-II

People with Urothelial Carcinoma are asked to participate in a research study being conducted by Montefiore Medical Center.

  • 06 Aug, 2021
  • 1 location
Paclitaxel-Avelumab for Angiosarcoma (ASAP)

To investigate the efficacy of Avelumab when given in combination with paclitaxel as a first line treatment for the patients with inoperable angiosarcoma.

  • 05 Mar, 2022
  • 1 location
Avelumab/Gemcitabine in Sarcomatoid RCC

To determine the feasibility and safety of avelumab and gemcitabine combination therapy in patients with metastatic sRCC.

  • 02 Mar, 2022
  • 1 location
NPC - AXEL Study : Axitinib-Avelumab

recurrent or metastatic NPC who failed at least first line chemotherapy. The combination of axitinib and avelumab has been studied in renal cell carcinoma (RCC). Based on the above promising and

  • 14 May, 2021
  • 1 location
Targeted Therapy and Avelumab in Merkel Cell Carcinoma

10.17 GoTHAM is intended as a signal-seeking, biomarker, phase Ib/II study that will evaluate the safety and anti-tumour activities of the novel combination of avelumab with 177-Lu-DOTATATE (a

  • 29 Apr, 2021
  • 6 locations
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

This research study is evaluating a drug called Avelumab alone and in combination with Talazoparib or Axitinib as a possible treatment for recurrent or metastatic endometrial cancer.

  • 27 Jan, 2022
  • 4 locations
Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line Treatment

A Phase 2 trial of avelumab plus gemcitabine in advanced leiomyosarcoma as a second line treatment

  • 11 Feb, 2021
  • 7 locations
Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Cancer immunotherapy with immunostimulatory antibodies targeting the CTLA-4 or PD-1/PD-L1 pathways has demonstrated its efficacy in variable proportions of cancer. For metastatic colorectal cancer (mCRC) it appeared that only the small subgroup of patients with MSI-H tumors (microsatellite instability-high phenotype) had a clinically meaningful response to the anti-PD-1- L1 antibodies. …

  • 26 Jan, 2021
  • 2 locations
Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma

This study aims to test if patients achieving a tumor response with the combination of axitinib plus avelumab, can discontinued the axitinib in order to delay the resistance to the anti VEGFR

  • 27 Jan, 2021
  • 20 locations
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) (ACTIW)

Patients will be randomized in phase II trials to continue on the same TKI versus one of the alternative treatment approaches. If a patient is not eligible for one of the treatments, he (she) will be randomized between the options for which he (she) is eligible. The trial will start …

  • 23 Feb, 2022
  • 16 locations